Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study)

Completed · Early Phase 1 · Has a placebo group

Conditions studied: Preeclampsia

In brief

Evaluation of the efficacy of postpartum 24 hour oxytocin infusion to reduce blood loss in patients with pre-eclampsia (PE)

Key facts

Study ID

NCT02221830

Run by

University of Colorado, Denver

People needed

66

Starts

2015-02-01

Expected to finish

2019-07-17

Last updated by the study team

2021-05-07

Who can join

Age: 13 and older, up to 45. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• vaginal or cesarean delivery at a gestational age greater than or equal to 20 weeks gestational age;
• diagnosis of preeclampsia (PE defined using standard definitions based on the ACOG bulletin and the NIH Working Group on High Blood Pressure in Pregnancy (i.e., a systolic blood pressure greater than 140 mm Hg or a diastolic blood pressure greater than 90 mm Hg on at least 2 occasions at least 6 hours apart after 20 weeks gestation and proteinuria of > 300mg per 24 hour period or > 1+ on dipstick).
• patients treated with magnesium sulfate for 24 hours post partum at 2g/hr (standard of care when deemed appropriate by clinician for seizure prophylaxis)

You may not qualify if…

• abnormal placentation (previa, accreta, etc)
• antenatal hemorrhage
• contraindication to oxytocin

Where it is running

• University of Colorado Clinical and Translational Research Center — Aurora, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.